FRI0225 THE EULAR/ACR 2018 AND SLICC 2012 HAVE INCREASED SENSITIVITY AGAINST THE ACR 1997 CLASSIFICATION CRITERIA AND CLASSIFY NON-OVERLAPPING GROUPS OF SLE PATIENTS: SIMULTANEOUS APPLICATION ASSURES THE GREATEST CAPTURE OF PATIENTS IN CLINICAL PRACTICE

Background: A joined EULAR/ACR initiative has proposed a new set of classification criteria for SLE based on weighted items and the use of ANA as an entry criterion. Objectives: To compare the diagnostic performance of the old and new classification criteria against physician diagnosis in an early SLE cohort and examine phenotypic and prognostic differences among patients who are classified with the criteria. Methods: Adult patients diagnosed by experienced physicians with SLE (n=690) or control diseases (n=301) during 2005-2016 and followed-up at least 6 months. All sets of criteria (ACR 1997, SLICC 2012, EULAR/ACR 2018) were applied. Hazard models were used to calculate elapsed time between the earliest item (of any criterion) and classification. Severity of SLE (BILAG-2004 glossary) and the SLICC/ACR organ damage index were determined. Results: The SLICC and EULAR/ACR had increased overall sensitivity as compared to the ACR criteria (91.3%, 88.6%, 85.7%, respectively; p 3 months in 17.3–19.9% of cases, particularly in neurological SLE (20.0–26.8%). Comparative analysis of patients who were missed by the criteria revealed significant differences in rates of individual clinical and serological features (Table 1) suggesting that existing criteria may classify non-overlapping groups of patients. Importantly, unclassified patients presented with a high prevalence of moderate/severe disease (43.3–60%) and organ damage (30–50%). Conclusion: Despite improved sensitivity and earlier classification with the EULAR/ACR and the SLICC criteria, still SLE diagnosis may be missed or delayed even in patients with moderate to severe disease, especially neurological-dominant disease. Simultaneous application in clinical practice assures the greatest capture of patients. Acknowledgement: This study received funding by the Hellenic Society of Rheumatology & Professionals Union of Rheumatologists of Greece (protocol number 644). Disclosure of Interests: Christina Adamichou: None declared, Dionisis Nikolopoulos: None declared, Irini Genitsaridi: None declared, Alessandra Bortoluzzi: None declared, Antonis Fanouriakis Paid instructor for: Amgen, GSK, Speakers bureau: Abbvie, Enorasis, Genesis Pharma, Emmanouil Papastefanakis: None declared, Eleni Kalogiannaki: None declared, Irini Gergianaki: None declared, Prodromos Sidiropoulos: None declared, Dimitrios Boumpas: None declared, George Bertsias: None declared